SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative ...
TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative ...
TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, ...
SL Science Holding Ltd. operates as a biomedical company. It operates through Exosome products, CD-19 Armed-T products, GDT cell therapy products, corporate and unallocated segments. The firm offers ...
Hosted on MSN
SL Science Holding, Alamos Gold and other big stocks moving lower in Monday’s pre-market session
U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd SLBT fell sharply in pre-market trading after the company reported ...
The ODD request was submitted pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Product: Vdelta2+ Gamma Delta T CellsDisease / Condition: Glioblastoma Multiforme ...
TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing ...
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. The research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results